Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a Healthcare company (Biotechnology) with a market capitalization of $4.5B. The Maz Rating grades it against the other companies in its sector.
Ionis Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.96, Ionis Pharmaceuticals, Inc. trades at 4.9x sales and 11.8x book value. Over the last twelve months it generated about $924M of revenue and a net loss of $532M. It runs a gross margin of 98.2%, an operating margin of -58.9% and a net margin of -56.9%. It shows return on equity of -120.4%, return on invested capital of -21.6% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 5.47 and a current ratio of 5.43. Over the past 52 weeks the share price ranged from $26.55 to $86.74, with a beta of 0.40.
Ionis Pharmaceuticals, Inc. does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 1 Strong Buy, 20 Buy and 12 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Ionis Pharmaceuticals, Inc. (IONS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 24.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.6% / 30% · Interest income / Revenue 8.05% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 24.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.3% / 33% · Receivables / Mkt Cap (36m) 1.14% / 49% · Interest income / Revenue 8.05% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 24.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.3% / 33.33% · Receivables / Mkt Cap (24m) 1.14% / 33.33% · Interest income / Revenue 8.05% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 63.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 66.3% / 33.33% · Receivables / Avg Assets (4Q) 2.23% / 33.33% · Interest income / Revenue 8.05% / 5% | Fail |
| FTSE | Debt / Total Assets 64.9% / 33.33% · (Cash+ST Inv) / Total Assets 64.7% / 33.33% · (Cash+Recv) / Total Assets 67.7% / 33.33% · Interest income / Revenue 8.05% / 5% | Fail |
No. As of September 2026, Ionis Pharmaceuticals, Inc. (IONS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Ionis Pharmaceuticals, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 8.05% of each dividend: Ionis Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.